Michael Yang, ViaCyte CEO

‘Dis­ap­point­ing’ Vi­a­Cyte da­ta raise ques­tions about fu­ture of com­pa­ny’s at­tempt­ed di­a­betes cure

Over the last 20 years, Vi­a­Cyte — un­der one name or an­oth­er — has pur­sued one of the most au­da­cious goals in biotech: a cure for type …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.